<DOC>
	<DOCNO>NCT01062490</DOCNO>
	<brief_summary>This multicenter , multinational , non-randomized , non-controlled open-label phase II trial evaluate safety efficacy treosulfan combination regimen fludarabine condition therapy prior allogeneic stem cell transplantation ( SCT ) patient MDS . The aim demonstrate clinical benefit compare historical data intravenous busulfan .</brief_summary>
	<brief_title>Treosulfan Based Conditioning Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Patients myelodysplastic syndrome , ( MDS ) accord WHO classification ( &lt; 20 % myeloblast peripheral blood bone marrow initial diagnosis ) indicate allogeneic transplantation 2 . Availability HLAidentical sibling donor ( MRD ) HLAidentical unrelated donor ( MUD ) HLAidentity define follow marker : HLAA , B , DRB1 , DQB1 . 3 . Target graft size ( unmanipulated ) bone marrow : 2 10 x 106 CD34+ cells/kg BW recipient least 2 x 108 nucleated cell /kg BW peripheral blood : 4 10 x 106 CD34+ cells/kg BW recipient 4 . Age &gt; 18 &lt; 60 year 5 . Karnofsky Index &gt; 80 % 6 . Adequate contraception female patient childbearing potential 7 . Written inform consent 1 . 'Secondary ' therapyrelated MDS know history exposure cytotoxic alkylating drug and/or radiation therapy 2 . Previous AMLinduction therapy two course ( e.g . case blast excess ) 3 . Previous allogeneic transplantation 4 . Severe concomitant illness / medical condition ( e.g . impaired respiratory and/or cardiac function ) 5 . Known manifested malignant involvement CNS 6 . Active infectious disease 7 . HIV positivity active hepatitis infection 8 . Impaired liver function ( Bilirubin &gt; upper normal limit ; Transaminases &gt; 3.0 x upper normal limit ) 9 . Impaired renal function ( Creatinineclearance &lt; 60 ml/min ; Serum Creatinine &gt; 1.5 x upper normal limit ) . 10 . Pleural effusion ascites &gt; 1.0 L 11 . Pregnancy lactation 12 . Known hypersensitivity treosulfan and/or fludarabine 13 . Participation another experimental drug trial within 4 week study 14 . Noncooperative behaviour noncompliance 15 . Psychiatric disease condition might impair ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Treosulfan</keyword>
	<keyword>MDS</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>leukemia</keyword>
	<keyword>Conditioning</keyword>
</DOC>